Pamidronate is ineffective for inflammatory-like low back pain associated with Modic type 1 changes: A double-blind,...

Area of Science:

• Orthopedics
• Pain Management
• Radiology

Background:

• Modic type 1 (MC-1) vertebral changes are linked to chronic low back pain (LBP) and inflammation.
• Pamidronate has shown promise for pain relief in bone marrow edema conditions.

Purpose of the Study:

• To assess the efficacy of intravenous pamidronate for inflammatory-like LBP with MRI-confirmed MC-1 changes.
• To evaluate pamidronate's impact on pain intensity, function, quality of life, and analgesic use.

Main Methods:

• A randomized, double-blind, placebo-controlled trial (PEPTIDE study) involving 44 adults with chronic LBP and MC-1.
• Participants received either pamidronate (90 mg daily for 2 days) or placebo, with primary endpoint at 3 months.

Main Results:

• No significant difference in VAS pain reduction between groups at 3 months.
• A trend towards pain improvement with pamidronate was observed at 6 weeks, but not sustained.
• Higher incidence of adverse events, mainly flu-like symptoms, in the pamidronate group.

Conclusions:

• Intravenous pamidronate offers a transient analgesic effect for MC-1 associated LBP at 6 weeks.
• Sustained clinical benefit was not observed at 3 or 6 months.
• Bisphosphonates may not be a long-term solution for this condition, with increased side effects.